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Abstract
Background: Despite considerable effort, the genetic factors responsible for .90% of the antibody deficiency syndromes
IgAD and CVID remain elusive. To produce a functionally diverse antibody repertoire B lymphocytes undergo class switch
recombination. This process is initiated by AID-catalyzed deamination of cytidine to uridine in switch region DNA.
Subsequently, these residues are recognized by the uracil excision enzyme UNG2 or the mismatch repair proteins MutSa
(MSH2/MSH6) and MutLa (PMS2/MLH1). Further processing by ubiquitous DNA repair factors is thought to introduce DNA
breaks, ultimately leading to class switch recombination and expression of a different antibody isotype.
Methodology/Principal Findings: Defects in AID and UNG2 have been shown to result in the primary immunodeficiency
hyper-IgM syndrome, leading us to hypothesize that additional, potentially more subtle, DNA repair gene variations may
underlie the clinically related antibody deficiencies syndromes IgAD and CVID. In a survey of twenty-seven candidate DNA
metabolism genes, markers in MSH2, RAD50, and RAD52 were associated with IgAD/CVID, prompting further investigation
into these pathways. Resequencing identified four rare, non-synonymous alleles associated with IgAD/CVID, two in MLH1,
one in RAD50, and one in NBS1. One IgAD patient carried heterozygous non-synonymous mutations in MLH1, MSH2, and
NBS1. Functional studies revealed that one of the identified mutations, a premature RAD50 stop codon (Q372X), confers
increased sensitivity to ionizing radiation.
Conclusions: Our results are consistent with a class switch recombination model in which AID-catalyzed uridines are
processed by multiple DNA repair pathways. Genetic defects in these DNA repair pathways may contribute to IgAD and
CVID.
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Introduction
Upon antigen stimulation, the constant region exons of the
expressed antibody heavy chain gene can be replaced with
downstream ones that encode an alternative antibody isotype (IgM
-. IgG, IgE or IgA). At the molecular level, antibody class switch
recombination (CSR) occurs between C/G-rich switch regions
upstream of each set of constant region exons (Figure 1). In recent
years a consensus model has emerged whereby CSR is initiated by
activation-induced deaminase (AID)-catalyzed cytidine deamina-
tion to uridine within switch region DNA [1–5]. These DNA
uridines are subsequently recognized and removed by the base
excision repair enzyme uracil DNA glycosylase 2 (UNG2) or the
mismatch repair proteins MutSa and MutLa (heterodimers of
MSH2/MSH6 and MLH1/PMS2, respectively) [2,6–13]. Addi-
tional base excision repair, mismatch repair, and recombination
repair factors are then proposed to help convert these DNA repair
intermediates to double-strand breaks and ultimately to CSR
products [14–19].
A subset of primary antibody deficiency syndromes has been
explained by defects in these DNA repair pathways. For instance,
hyper-IgM syndrome type 2 (HIGM2) is caused by mutations in
AID and this disease is characterized by high levels of IgM at the
expense of the other antibody isotypes ([20]; reviewed in [21]).
Mutations in UNG2 lead to the less severe HIGM5 [22], and
defects in PMS2 have been associated with decreased antibody
production [23]. Varying degrees of antibody deficiency have also
been noted in chromosomal instability syndromes such as ataxia-
telangiectasia (A-T, ATM mutations), Nijmegen breakage syn-
drome (NBS, NBS1 mutations), and ataxia-telangiectasia-like
disorder (ATLD, MRE11 mutations) [24–30].
Prior studies have shown that missense mutations that impair
MSH5 binding to its obligate heterodimerization partner MSH4
associate with immunoglobulin A deficiency (IgAD) and common
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occur in different individuals of the same family, suggesting a
common genetic components in at least a subset of patients [32].
Mutations in the B cell surface receptor genes TACI [33–35] and
CD19 [36,37], and the T cell receptor gene ICOS [38] are also
responsible for a subset of CVID cases. Nevertheless, despite this
considerable progress, the genetic causes of .90% of IgAD and
CVID cases have yet to be identified (reviewed in [39–41]).
Given that defects in DNA metabolism proteins are responsible
for a fraction of primary antibody deficiencies, we hypothesized
that variations in DNA repair genes could also underlie additional
IgAD and CVID cases. To test this hypothesis, we performed a
genetic association study of 27 candidate DNA metabolism genes
in IgAD/CVID. Based on those results, we sequenced selected
genes in a panel of 96 IgAD/CVID patients and subsequently
genotyped the non-synonymous alleles we identified in a large
case-control association study. Novel coding and non-coding
variations were detected in several genes, including seven rare
variants found only in IgAD and two specific to CVID. Four of
these mutations, MLH1-S247A, MLH1-Q409P, NBS1-P401R, and
RAD50-Q372X showed significant association with IgAD/CVID.
One IgAD patient carried three previously unreported mutations,
MSH2-A727S, MLH1-G638R, and NBS1-P401R. A second IgAD
patient was compound heterozygous for RAD50-P165H and the
previously reported RAD50-R327H variation. Two novel single
nucleotide polymorphisms (SNPs) in the 39 untranslated region of
MRE11 were also associated with CVID. Finally, both patient-
derived and purposefully engineered cells harboring the RAD50-
Q372X mutation exhibited increased sensitivity to ionizing
radiation.
Results
IgAD/CVID association screen of 27 DNA repair genes
To screen for candidate genes in IgAD and CVID, we
genotyped 140 IgAD patients, 48 CVID patients, and 92 healthy
controls for SNPs selected from 26 known DNA repair genes and
AID (collectively these genes define several DNA metabolism
pathways). To test if a given SNP was associated with IgAD and/
or CVID, allele frequencies were compared to the healthy control
cohort. Significant single marker associations with IgAD and/or
CVID (p,0.01) were noted for SNPs in the mismatch repair
complexes, MutSa, MutSb, and MutSc, the MRN complex, the
extended RAD52 epistasis group, and AID. A summary of single
marker associations with p-values ,0.01 is presented in Table 1.
Full association data can be found in Table S1.
To further refine the list of candidates, we performed a relaxed
correction for multiple testing by permutation testing markers
grouped by DNA repair complex or pathway. After applying this
statistical method, 13 SNPs remained significantly associated with
IgAD/CVID (Table 1). Markers in RAD54B (rs3019279), AID
(rs2580874 and rs714629) showed significant association with the
combined IgAD/CVID cohort, and SNPs in MSH2 (rs3771276
and rs6729015), RAD50 (rs2237060), and RAD52 (rs10849605)
were associated with IgAD. In agreement with our prior studies,
six markers in the MHC class III region gene MSH5 were
associated with IgAD [31].
Next, we constructed multi-marker haplotypes and tested for
association with IgAD and/or CVID. The markers comprising
each haplotype block are listed in Table S2 and association data
for haplotypes with a frequency greater than 0.1% are reported in
Table S3. Significantly associated haplotypes with an uncorrected
p-value less than 0.01 are summarized in Table 2. After pathway-
based permutation testing, haplotypes of MLH1, MSH5, and
MUS81 were associated with IgAD and the combined IgAD/
CVID group. Association with CVID was noted for haplotypes of
MSH2 and RAD50.
Identification of novel IgAD/CVID alleles
Since notable IgAD/CVID associations were observed for
genes encoding DNA repair proteins that could convert AID-
catalyzed uracils into DNA breaks, we resequenced select DNA
repair genes in IgAD and CVID patient samples. Specifically, we
sequenced the MutSa genes MSH2 and MSH6, the MutLa gene
MLH1, and the MRN complex genes MRE11, RAD50, and NBS1.
The genes encoding AID, APEX1, ERCC1, and RAD52 were
also sequenced.
In all, 242 genetic variants were detected, of which, 93 did not
have records in dbSNP or SwissProt and were therefore
considered novel (Table S4). 24 alleles encoded amino acid
changes, 13 of which were previously unreported (all detected in a
heterozygous state). Of the remaining 80 novel SNPs, 5 were
synonymous coding alleles, 31 were located in mRNA untrans-
lated regions (UTRs), 40 were intronic, and 4 were in flanking
non-transcribed regions.
We next determined the allele frequencies of identified non-
synonymous alleles and selected UTR, synonymous, and intronic
SNPs in a large cohort of healthy controls, IgAD patients, and
CVID patients. The most significant data are summarized in
Table 3, and full datasets can be found in Table S5. In the
mismatch repair pathway, two novel MSH2 variations were
Figure 1. A model for DNA break generation by repair enzymes
in class switch recombination. AID initiates CSR by deaminating
switch (S) region DNA cytosines to uracils (the m and a constant regions
are depicted). These uracils are recognized and excised by the base
excision repair enzyme UNG2 or the mismatch repair complex
consisting of MutSa (MSH2/MSH6) and MutLa (PMS2/MLH1). The
endonuclease activity of APEX1 or the MRN complex (MRE11-RAD50-
NBS1) could then convert UNG2-generated abasic sites to single-strand
breaks. The mismatch repair pathway (MSH2/MSH6, EXO1, MLH1/PMS2)
could also introduce single-strand breaks at mismatched G:U bases.
Opposing single-strand breaks may naturally lead to double-strand
breaks, which can be further processed by non-homologous end
joining factors to yield a complete CSR event. A switch from IgM to IgA
is depicted, and the intervening switch circle is not shown.
doi:10.1371/journal.pone.0012260.g001
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The latter variation was unique to a single IgAD patient. Four
novel amino acid mutations were detected in MLH1. MLH1-
S247A and MLH1-G638R were specific to IgAD and MLH1-
Q409P was specific to CVID (Table 3). MLH1-H727L and the
previously reported mutations MLH1-K618A, MLH1-V716M, and
MLH1-I219V occurred at similar frequencies in IgAD/CVID
patients and controls.
The most striking variations were observed in RAD50. In all, 16
novel SNPs were found: 3 encoded amino acid changes, 2 were
located in the 59 UTR, 1 was synonymous, and 10 were intronic
(Table S4). Most notably a single CVID sample contained the
heterozygous transition mutation (1114C.T) that creates a
premature stop codon at amino acid 372 (RAD50-Q372X,
Table 3). One IgAD patient carried RAD50-R1077Q and another
had both RAD50-P165H and RAD50-R327H. RAD50-R327H
was also detected in our control samples, but never linked with
RAD50-P165H. Pedigree analysis of the RAD50-P165H/R327H
patient revealed that the two alleles were present in a compound
heterozygous state.
Novel variations were also detected in the other two MRN
complex genes, MRE11 and NBS1.I nMRE11, 18 novel SNPs
were detected (Table S4). Of these, two resulted in amino acid
changes (MRE11-A492D and MRE11-E494K), eight were in the
39 UTR, and eight were intronic. Both MRE11-A492D and
MRE11-E494K were found at similar frequencies in controls and
IgAD/CVID cases (Table 3). Two 39 UTR SNPs, ss206257789
and ss206257804, were, however, significantly enriched in the
CVID population. In NBS1, 11 unreported SNPs were detected
(Table S4). Three were non-synonymous, and the remaining 8
were a mixture of synonymous, 59 UTR, 39 UTR, and intronic.
Two novel alleles, NBS1-P401R and NBS1-D527Y, were specific
to IgAD (Table 3). NBS1-V210F and NBS1-L421S were detected
in IgAD/CVID and control samples, as was the previously
reported common polymorphism, rs1805794 (NBS1-E185Q).
A number of previously unreported SNPs were also discovered
in other genes. In AID, two novel 39 UTR SNPs and three novel
synonymous SNPs were detected (Table S4). Two novel SNPs
were found in APEX1, one synonymous and one in the 59 UTR.
The previously reported 59 UTR SNP rs2307490 showed modest
association with CVID (Table 3). In ERCC1, one 39 flanking SNP
and five novel intronic SNPs were detected (Table S4). 18 new
SNPs were discovered in RAD52, 14 in the 39 UTR, and four in
introns. No amino acid substitution mutations variations were
detected in these four genes.
While no patients were homozygous for any single SNP, some
patients were found to carry mutant alleles in more than one DNA
repair gene. An IgAD patient heterozygous for the previously
reported APEX1-Q51H allele also carried three novel mutations,
MLH1-G638R, MSH2-A727S, and NBS1-P401R. One IgAD
Table 1. SNPs in multiple DNA repair genes associate with IgAD/CVID.
Controls IgAD CVID Combined IgAD & CVID
Gene SNP
Allele
Frequency
Allele
Frequency p-Value
Corrected
p-Value
a
Allele
Frequency p-Value
Corrected
p-Value
a
Allele
Frequency p-Value
Corrected
p-Value
a
MSH2
b rs4952887 14/184 31/280 0.22 0.96 18/96 0.0054 0.062 49/376 0.06 0.49
MSH2
b rs2347794 60/182 117/278 0.049 0.42 47/94 0.0059 0.070 164/372 0.012 0.17
MSH2
b rs3771274 62/184 118/278 0.059 0.46 49/96 0.0049 0.053 167/374 0.013 0.18
MSH2
b rs3771275 64/184 117/276 0.10 0.77 48/94 0.0088 0.098 165/370 0.027 0.30
MSH2
b rs3771276 59/182 116/276 0.038 0.34 48/96 0.0042 0.0498 164/372 0.0085 0.13
MSH2
b rs6729015 61/184 122/278 0.021 0.22 49/96 0.0036 0.045 171/374 0.0046 0.061
MSH2
b rs3771281 56/184 116/280 0.016 0.19 43/96 0.017 0.21 159/376 0.0068 0.079
RAD50 rs2237060 59/184 117/280 0.035 0.23 48/96 0.0034 0.029 165/376 0.0073 0.057
RAD52 rs9634161 28/184 54/280 0.26 1.00 27/96 0.0099 0.26 81/376 0.076 0.88
RAD52 rs10849605 75/178 123/276 0.61 1.00 59/94 0.0012 0.040 182/370 0.12 0.97
RAD54B rs2046666 71/184 143/280 0.0083 0.23 46/96 0.13 0.98 189/376 0.0092 0.26
RAD54B rs3019279 63/184 134/276 0.0024 0.076 47/94 0.011 0.29 181/370 0.0010 0.035
RAD54B rs2921385 71/182 145/276 0.0045 0.14 48/96 0.078 0.89 193/372 0.0044 0.13
RAD54B rs2930968 64/184 132/280 0.0084 0.23 47/94 0.014 0.35 179/374 0.0034 0.11
AID rs2580874 73/184 151/280 0.0026 0.010 52/96 0.021 0.021 203/376 0.0015 0.0055
AID rs1561559 2/184 15/280 0.017 0.068 2/94 0.49 0.49 17/374 0.034 0.13
AID rs714629 73/178 142/274 0.024 0.086 49/90 0.037 0.037 191/364 0.012 0.044
MSH5 rs805304 68/182 170/280 9.2E-07 0E-00
c 37/94 0.75 1.00 207/374 6.9E-05 0.0020
MSH5 rs3117572 142/182 251/278 2.7E-04 0.0064 76/96 0.83 1.00 327/374 0.0042 0.090
MSH5 rs3131379 27/182 87/278 6.4E-05 0.0016 14/92 0.93 1.00 101/370 0.0011 0.024
MSH5 rs3131378 26/182 89/280 2.1E-05 5E-04 18/96 0.33 1.00 107/376 2.3E-04 0.0060
MSH5 rs3117577 26/180 88/278 3.2E-05 9E-04 15/96 0.79 1.00 103/374 6.4E-04 0.016
MSH5 rs707938 63/180 154/276 1.4E-05 3E-04 35/96 0.81 1.00 189/372 4.7E-04 0.012
a) Corrected for multiple testing bias by permutation testing as described in Materials and Methods.
b) Corrected p-values derived using MutSa complex SNPs.
c) No permutations exceeded those observed for SNP rs805304.
doi:10.1371/journal.pone.0012260.t001
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tionally, as described earlier, an IgAD patient was found to be
biallelic for RAD50-P165H and RAD50-R327H. These observa-
tions hint that the combinatorial effects of multiple mutations may
underlie a subset of IgAD/CVID cases.
RAD50-Q372X confers sensitivity to ionizing radiation
Since CSR is likely to involve DNA breakage and end
processing by exonucleases, we next decided to test the effect of
one of the identified mutations (RAD50-Q372X) on cellular DNA
repair capacity. To this end, immortalized B lymphoblast lines
were generated from the CVID patient carrying RAD50-Q372X.
Immunoblotting experiments indicated that RAD50 protein levels
were reduced approximately 2-fold compared to three similarly
derived cell lines from individuals with no detected RAD50
mutation (Figure 2a). MRE11 levels were also reduced approx-
imately 2-fold, consistent with prior reports indicating that all
three components of the MRN complex are subject to coordinated
post-translational regulation [27]. Compared to a control EBV
immortalized cell line, the Q372X cells were modestly, but
significantly, sensitive to higher doses of ionizing radiation, but
not to the extent of cells derived from an ataxia telangiectasia
patient (Figure 2b).
To overcome the natural variability associated with patient-
derived cell lines, we asked if we could recapitulate the sensitivity
to ionizing radiation by introducing the RAD50 c.1114C.T
mutation encoding for RAD50-Q372X into the endogenous locus
of an immortalized human colon cancer cell line HCT116
(Figure 2c). HCT116 is a near-diploid line that has been used
extensively in gene targeting experiments, particularly for studies
of DNA metabolism proteins [42]. Targeting events were
identified by insertion-specific PCR and confirmed by Southern
blot using a flanking probe. Specific incorporation of the
c.1114C.T mutation was confirmed by sequencing insertion-
specific PCR products. Cells containing the heterozygous
c.1114C.T mutation displayed an increased sensitivity to ionizing
radiation compared to the control parental line, non-targeted sister
clones, or targeted sister clones in which the mutation was not
integrated (Figure 2d and data not shown). In comparison, a
DNA-PKcs-deficient HCT116 cell line showed higher levels of
ionizing radiation sensitivity [42]. These results demonstrate that
the RAD50-Q372X mutation impairs the ability of the MRN
complex to repair ionizing radiation-induced DNA double strand
breaks.
Discussion
We have shown that variations in multiple DNA repair
pathways show association with the primary immunodeficiency
syndromes CVID and IgAD. To our knowledge this is the first
report associating immunodeficiency with markers in many of
these genes, notably MSH2, MLH1, and RAD50. We also
identified new non-synonymous alleles of MSH2, MLH1, RAD50,
and NBS1, and UTR SNPs in RAD50 and MRE11 that were
unique to IgAD and/or CVID. Cells carrying one of these
mutations, RAD50-Q372X, were incapable of wildtype levels of
recombination repair, likely due to haploinsufficiency. Overall,
these data suggest that variations in the mismatch and recombi-
nation repair pathways may underlie some IgAD and CVID cases.
Mismatch repair proteins directly recognize and excise single
base DNA mismatches and short patches of mismatched DNA
(reviewed in [43]). Genetically, the involvement of mismatch
repair in CSR has been well established in mice, with the most
prominent defects observed in animals that also lack the uracil
Table 2. Haplotypes blocks in MLH1, MSH2, RAD50, and RAD54B associate with IgAD/CVID.
IgAD CVID Combined IgAD & CVID
Haplotype Hap Freq p-Value
Corrected
p-Value
a Hap Freq p-Value
Corrected
p-Value
a Hap Freq p-Value
Corrected
p-Value
a
MSH2 – Block 16
GCGACGCG 0.575 0.079 0.400 0.568 0.0075 0.0250 0.558 0.013 0.066
MSH3 – Block 18
GTT 0.137 0.64 1.00 0.171 0.0097 0.14 0.157 0.19 1.00
MSH3 – Block 19
GTC 0.009 0.014 0.20 0.014 0.14 0.95 0.007 0.0043 0.075
MLH1 – Block 11
ATTATAT 0.008 0.018 0.036 0.013 0.16 0.64 0.006 0.0062 0.014
RAD50 – Block 23
TGAGCA 0.365 0.064 0.500 0.367 0.0062 0.041 0.386 0.011 0.097
TGATCA 0.4 0.37 1.00 0.368 0.0038 0.024 0.373 0.061 0.63
RAD54B –B l o c k2 6
TAGGGCT 0.508 0.0062 0.15 0.55 0.086 0.96 0.503 0.0057 0.16
MSH5 – Block 21
TACGATT 0.139 2.0E-04 0.0033 0.211 0.94 1.00 0.15 0.0066 0.095
TGCAGCC 0.243 7.5E-05 0.0010 0.146 0.99 1.00 0.227 0.0017 0.023
MUS81 – Block 22
AATCA 0.011 0.0053 0.014 0.018 0.11 0.50 0.009 0.0014 0.0054
a) Corrected for multiple testing bias by permutation testing as described in Materials and Methods.
doi:10.1371/journal.pone.0012260.t002
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inactivating mutations in the mismatch repair proteins MSH2,
MSH6, MLH1, or PMS2 are at increased risk for developing
hereditary non-polyposis colorectal cancer (HNPCC) [44,45]. IgA
deficiency has been noted in a handful of HNPCC patients, one
with a homozygous MSH2 mutation [46] and three with biallelic
MSH6 mutations [47,48].
Our results are consistent with a role for mismatch repair in
CSR. Most of the IgAD/CVID-specific alleles that we detected in
the mismatch repair pathway are located in functionally important
domains. MSH2-A727S maps to a conserved ABC domain (amino
acids 718-731) that is predicted to be involved in ATP hydrolysis
[49] (Figure 3). Two of the three IgAD/CVID specific mutations
identified in MLH1 map to domains of known importance.
MLH1-S247A is located in a region that has both nucleotide
hydrolysis and signal transduction functions [50]. Mutation of this
residue to proline (S247P) has been reported in 14 HNPCC2
patients and is associated with decreased MLH1 protein
expression and impaired mismatch repair activity using an in-vitro
assay [51]. MLH1-G638R introduces a positively charged amino
acid into a neutral area of the region known to be important for
interaction with PMS2, MLH1, and PMS1 [52,53]. Interestingly,
two additional rare alleles that we detected in both IgAD/CVID
cases and control samples were previously identified and
characterized in HNPCC studies. MLH1-K618A was suggested
to bind less efficiently to PMS2 [54], however follow-up studies
with this allele found PMS2 binding and overall mismatch repair
function to be normal [51]. The MLH1-V716M variant has been
suggested to be a protective allele, as it was found enriched in
controls compared to HNPCC cases [55]. Taken together, these
results indicate that cancer predisposition alleles that are DNA
damage sensitizing may also perturb the ability of the DNA repair
pathways to elicit CSR.
Our results are the first to implicate MRN defects in IgAD/
CVID. The premature stop codon encoded by the RAD50-Q372X
allele likely leads to nonsense-mediated decay of the mRNA and
haploinsufficiency (Figure 4). Other identified mutations may
slightly perturb the structure and/or function of the MRN
complex, and could act as weak hypomorphic alleles. The
RAD50-P165H mutation replaces a neutral, non-polar proline
Table 3. Genetic association of SNPs identified by reseqencing.
Controls IgAD CVID
Gene SNP Variant Allele Frequency Allele Frequency p-Value Allele Frequency p-Value
MSH2 rs104895022 T292S 1/1890 2/652 0.10 0/230 0.73
MSH2 rs104895022 A727S 0/1888 1/650
a 0.088 0/230 —
MLH1 rs1799977 I219V 563/1904 187/656 0.61 79/222 0.065
MLH1 rs104894996 S247A 0/1876 2/642 0.016 0/230 —
MLH1 rs104895000 Q409P 0/1902 0/656 — 1/230 0.0040
MLH1 rs35001569 K618A 13/1882 5/646 0.83 2/230 0.76
MLH1 rs63750549 G638R 0/1872 1/642
a 0.088 0/230 —
MLH1 rs35831931 V716M 3/1904 1/658 0.98 1/230 0.36
MLH1 rs104895002 H727L 1/1872 0/642 0.56 1/228 0.075
RAD50 rs104895040 59 UTR 0/1842 1/640 0.090 0/230 —
RAD50 rs104895041 59 UTR 0/1900 1/658 0.089 0/230 —
RAD50 rs104895041 P165H 0/1842 1/640 0.0897 0/230 —
RAD50 rs28903091 R327H 4/1826 1/584 0.83 0/214 0.49
RAD50 rs104895046 Q372X 0/1900 0/654 — 1/230 0.0040
RAD50 rs104895051 R1077Q 0/1856 1/596 0.078 0/216 —
RAD50 rs104895053 SYN 0/1900 1/652 0.088 0/230 —
MRE11 rs104895004 39 UTR 2/1866 2/636 0.26 3/228 4.0E-04
MRE11 rs104895010 39 UTR 0/1864 0/636 — 1/228 0.0042
MRE11 rs104895016 A492D 2/1898 3/652 0.077 1/230 0.21
MRE11 rs61749249 E494K 8/1876 0/642 0.098 2/230 0.36
NBS1 rs104895039 Intron 0/1814 1/602
a 0.083 0/226 —
NBS1 rs1805794 E185Q 625/1892 207/650 0.58 77/224 0.69
NBS1 rs61754796 V210F 4/1858 2/638 0.66 0/230 0.48
NBS1 rs104895033 P401R 0/1892 2/646
a 0.016 0/230 —
NBS1 rs104895032 L421S 1/1884 0/644 0.56 1/230 0.076
NBS1 rs104895031 D527Y 0/1844 1/598 0.079 0/212 —
RAD52 rs7487683 G180R 74/1876 17/644 0.13 9/230 0.98
APEX1 rs2307490 59 UTR 3/1872 2/642 0.46 2/230 0.037
APEX1 rs1048945 Q51H 60/1840 12/626 0.085 9/212 0.45
a) A single IgAD patient carried all four alleles, MLH1-G638R, MSH2-A727S, NBS1-P401R, and the intronic SNP rs104895039.
doi:10.1371/journal.pone.0012260.t003
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evolutionarily conserved through vertebrates. This residue is just
outside of the N-terminal NTPase-containing globular domain
and at the edge of the region that is thought to be important for
interaction with MRE11. At the edge of the N-terminal MRE11-
interating domain, RAD50-R1077Q replaces a conserved, posi-
tively charged arginine with a neutral glutamine. RAD50-R327H,
which by itself did not associate with IgAD/CVID, exchanges one
neutral, polar residue for another in the N-terminal coiled-coil
domain. Neither of the additional IgAD/CVID-specific alleles
detected in the MRN complex, NBS1-P401R and NBS1-D527Y,
disrupt known or predicted functionally important protein
domains. Future studies on the detected MRN alleles will provide
greater insight into how they functionally impact recombination
repair and CSR.
The association noted for two markers in AID suggests that a
subclass of IgAD/CVID syndromes may be due to variations at
this locus. These markers may be linked to undiscovered alleles
that impact the expression of functional AID. This could be due to
variations that create splice variants, UTR mutations that impact
mRNA stability and protein expression, or mutations that impact
transcription of AID, including alterations to transcription factor
binding sites or sites important for epigenetic modulation of
expression. In these studies, we identified two novel SNPs in the
AID UTR and three novel synonymous mutations (Table S4). The
further studies of these alleles may yield that some IgAD/CVID
patients represent a new subclass of Hyper-IgM type 2 patients.
Overall, these studies suggest that, like many cancer predispo-
sition syndromes such as HNPCC, IgAD and CVID may be a
heterogeneous class of diseases due to defects in multiple pathways.
Rather than straightforward causal alleles giving rise to disease,
IgAD and CVID alleles likely represent risk factors that predispose
an individual to developing immune deficiency. Additional studies
to determine what effects these unique variations have on DNA
repair and CSR are ongoing and long-term.
Materials and Methods
Ethics Statement
The Karolinska Institutet human subjects research review board
provided written approval for the informed collection of DNA
samples from CVID/IgAD patients for sequence analysis. The
sample identities were unknown to the University of Minnesota
team and therefore this arm of the project was exempt from
institutional review.
Human DNA samples
The initial association screen was performed in DNA from 140
IgAD patients, 48 CVID patients, and 92 healthy controls. To
characterize all coding variation for the selected candidate genes in
the CVID population, genomic resequencing was performed in 58
CVID DNAs, 48 from the original population and 10 that were
subsequently recruited. 38 IgAD patients, each carrying at least
one allele/haplotype associating with disease, were also included.
334 IgAD patients, 108 CVID patients, and 991 healthy controls
were used for the subsequent large genetic association study of
detected non-synonymous SNPs. Where adequate DNA was
available, samples that had been used for earlier studies were
utilized. All DNA samples used in this study were collected from
unrelated individuals of self-reported Swedish descent and isolated
at the Karolinska Institutet (Stockholm, Sweden). Informed
consent was obtained from all subjects, and these studies were
approved by the Karolinska Institutet human subjects research
institutional review board.
Figure 2. Heterozygous RAD50-Q372X cells show increased
sensitivity to ionizing radiation. (A) Immunoblot of lysates from
lymphoblast cell lines derived from the CVID patient carrying RAD50-
Q372X and three CVID patients with no mutations in RAD50, MRE11, or
NBS1 (wildtype, wtRAD50). (B) Viability of patient derived cell lines after
exposure to ionizing radiation. Lymphoblast cell lines from the RAD50-
Q372X patient (diamonds) and a CVID patient with no mutations in
RAD50, MRE11,o rNBS1 (triangles) were exposed to the indicated doses
of ionizing radiation and cell viability was assessed by Propidium Iodide
staining and flow cytometry 10 days post-exposure. The Coriell cell line
GM08436 (filled circles), containing heterozygous truncating mutations
in ATM, was included as a positive control (Coriell Cell Repositories).
Error bars denote the standard error of triplicate treatments. (C) The
targeting strategy used to introduce the c.1114C.T mutation into the
endogenous RAD50 locus. Exons 7, 8, and 9 are depicted by boxes, and
the position of c.1114C.T in exon 8 is marked. (D) Ionizing radiation
sensitivity profiles of G418 resistant targeted clones with c.1114C.T
(diamonds) or a wildtype RAD50 exon 8 (triangles). It is notable that
both of these clones have properly integrated drug resistance cassette,
and they only differ by whether or not the flanking C-to-T mutation was
co-recombined. The parental HCT116 cell line shows an ionizing
sensitivity profile superimposable with that of the wildtype exon 8
clone (data not shown). DNA-PKcs-deficient cells [42] (circles) are
extremely IR sensitive. Error bars represent the standard error of the
mean sensitivity of four independent subclones (each assayed in
duplicate).
doi:10.1371/journal.pone.0012260.g002
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For the initial association screen, tag SNPs were selected to
cover the genomic locus of each gene plus an additional 10 kb
upstream and 5 kb downstream using Tagger [56]. As phase II
hapmap data was not yet available at the time, phase I data was
used. Additional non-tag SNPs were included to fill out the assay.
Genotypes were determined using the Illumina GoldenGate
platform at the Broad Institute. Of the 384 markers genotyped,
81 failed to pass quality control tests and were not used in
subsequent studies (Table S6). Two markers rs2020908 and
rs689754 deviated significantly from Hardy-Weinberg equilibrium
in the control DNA set (p,0.001), and 79 markers had genotype
call rates that were below the 90% confidence threshold.
Therefore, a total of 303 SNPs passed quality control criteria
and were used in the subsequent studies.
For the large genetic association study, genotyping was
performed by the BioMedical Genomics Center at the University
of Minnesota. Two Sequenom iPLEX gold genotyping assays were
designed using Spectrodesigner, part of the MassARRAY software
package, to include non-synonymous coding SNPs detected by
resequencing. Assays were filled out by including synonymous
coding SNPs, UTR SNPs, and intronic SNPs located within 10
bases of an exon. Primers were synthesized by IDT and sequences
are available upon request.
DNA repair gene resequencing
Primer design, sequencing, and polymorphism detection were
performed by the Broad Institute Center for Genotyping and
Analysis. Briefly, primers were designed for each target gene to
sequence the known exons, the 59 UTR, and the 39UTR, with at
least 100 nucleotides of flanking sequence on each side. Genetic
variants were identified by a combination of the PolyPhred and
PolyDhan programs. Primer sequences for each assay are available
upon request. To increase the power to detect informative alleles,
the sample set was enriched for DNAs that carried disease-
associated single markers and haplotypes as determined in the
initial genotyping screen. In all, 3,086,784 nucleotides were
examined, with average 16coverage of 92.0% and 26coverage
of 88.4% (Tables S7). All novel non-synonymous SNPs were
confirmed by fluorescence-based Sanger di-deoxy sequencing at
either the University of Minnesota Sequencing and Analysis
Facility or the Macrogen Company (South Korea).
Data processing and statistical analyses
For both genotyping studies, allele calls were made using the
appropriate built-in automatic allele calling specific to each
platform. Call clustering was inspected manually and adjusted
when obvious calling errors were made by the software. For
genetic association studies, we required that each SNP have a
missing genotype rate ,10% and, in controls, have a Hardy-
Weinberg p-value .0.001. Samples were excluded if genotyping
failed for .50% of markers. Haploview was used to determine
haplotype structure from control genotypes and to perform
association testing for both single markers and haplotypes [57].
To correct for multiple testing bias, association results were
subjected to 100,000 permutation tests bypathway using Haploview.
For this analysis, genes were grouped based on functional pathways.
Each group that contained at least one marker or haplotype with an
uncorrected p-value ,0.01 was permuted. These pathways were
MutSa (MSH2 and MSH6), MutSb (MSH2 and MSH3), MutLa
(MLH1 and PMS2), MRN (MRE11, RAD50, NBS1), MutSc (MSH4
and MSH5), and RAD51-mediated homologous recombination
Figure 3. Location of the amino acid variations in the mismatch repair proteins MSH2 and MLH1. (A) MSH2 is divided into four domains.
MutSI, II, and III represent a DNA binding globular region, an RNaseH-like motif, and a major structured domain, respectively, revealed by the Thermus
aquaticus MutS crystal structure [59]. The fourth domain is an ABC-type ATPase domain [49]. (B) MLH1 has three domains, a histidine kinase-like
ATPase domain (HATP), a MutL transducer domain (MutL-T), which is homologous to a domain in DNA gyrase B, and a PMS2 interaction domain
(PMS2-ID). The indicated amino acid variations lie within conserved regions. Mutations associated with IgAD or CVID are denoted by {, those that
were unique to the IgAD/CVID cohort but did not reach statistical significance are denoted by {. The illustrated protein segments were derived from
ClustalW reference sequence alignments of the human, mouse, chicken and zebrafish proteins (MSH2, NP_000242, NP_032654, XP_426110, and
NP_998689; MLH1, NP_000240, NP_081086, XP_418828, and NP_956953).
doi:10.1371/journal.pone.0012260.g003
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permuted on an individual gene basis. Permutation testing was
conducted for SNPs and haplotypes independently.
RAD50-Q372X heterozygous cell lines
EBV-immortalized lymphoblast lines were generated at the
Karolinska Institutet (Stockholm, Sweden). The HCT116-
RAD50-c.1114C.T( Q372X) knock-in cell line and a wildtype
knockin control line were generated using recombinant adeno-
associated virus (rAAV)-assisted gene targeting, as previously
described [42]. Briefly, targeting arms were amplified from
genomic DNA by PCR and cloned into pJET1.2 (CloneJet PCR
kit, Fermentas). Site directed mutagenesis was used to introduce
the RAD50 c.1114C.T stop mutation and targeting arms were
assembled into pNeDaKO [58]. rAAV was produced in HEK-
293T cells and used to transduce HCT116 cells. The resulting
G418-resistant clones were screened for targeted insertion by PCR
and confirmed by Southern blotting. The introduction of the
mutation was confirmed by sequencing.
Immunoblots and ionizing radiation sensitivity experiments
Cell extracts were prepared using RIPA buffer, fractionated by
SDS PAGE, and transferred to PVDF membrane for immunoblot-
ting. The membranes were probed with antibodies to RAD50
(Novus), MRE11 (Genetex), or tubulin (Bethyl) followed by
appropriate HRP-conjugated secondary antibodies (BioRad).
Radiation sensitivity assays were conducted exposing cultures in a
cesium irradiator for the indicated doses. Cell viability was assayed
by Propidium Iodide staining and flow cytometry (lymphoblasts) or
crystalviolet colony staining of plateddilutions (HCT116 cells) [42].
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0012260.s001 (0.12 MB
PDF)
Table S2
Found at: doi:10.1371/journal.pone.0012260.s002 (0.04 MB
PDF)
Table S3
Found at: doi:10.1371/journal.pone.0012260.s003 (0.09 MB
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Found at: doi:10.1371/journal.pone.0012260.s004 (0.07 MB
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Figure 4. Location of the amino acid variations in the recombination proteins MRE11, RAD50, and NBS1. (A) A schematic of the MRN
complex, indicating two copies of each protein and the extended coil-coil and zinc hook domains of RAD50. (B, C, & D) Schematics depicting the
major protein domains of RAD50, MRE11, and NBS1, with the IgAD/CVID amino acid variations shown below aligned to the homologous regions of
mouse, chicken, and zebrafish proteins. RAD50 has an N-terminal Walker A-type ATPase and DNA binding domain (ABC), three coiled-coil regions
(CC), a zinc-hook (Zn), and a C-terminal Walker B-type ATPase and DNA binding domain (ABC). MRE11 has a protein phosphatase 2A-like catalytic
domain (PP2AC) and a DNA binding domain (DNA BD). NBS1 has forkhead homology region (FHA) and a BRCA1 C-terminus-like domain (BRCT). A box
in NBS1 indicates the location containing most of the mutations responsible for Nijmegen breakage syndrome. Mutations associated with IgAD or
CVID are denoted by {, those that were unique to the IgAD/CVID cohort but did not reach statistical significance are denoted by {. The illustrated
protein segments were derived from ClustalW reference sequence alignments (RAD50, NP_005723, NP_033038, XP_414645, and XP_696859; MRE11,
NP_005582, NP_061206, NP_990109, and NP_001001407; NBS1, NP_002476, NP_038780, NP_989668, and NP_001014819).
doi:10.1371/journal.pone.0012260.g004
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